Emerging Therapies Plaque Psoriasis

New guidance statements related to COVID-19 vaccines and psoriatic disease patients have been published by the National Psoriasis Foundation (NPF) COVID-19 Task Force.

Several systemic therapies are currently available for the treatment of patients with moderate-to-severe psoriasis. Biologics changed the game for treatment. Continued study of and innovation in IL-17 and IL-23 inhibitors promise even better results, but clinicians need to understand each biologic in detail.

A recent study found patients with high baseline cardiovascular risk who had taken ustekinumab were at increased risk for developing severe cardiovascular events following treatment.